IDYA
Price
$27.17
Change
+$1.34 (+5.19%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
2.38B
67 days until earnings call
VNDA
Price
$4.61
Change
-$0.03 (-0.65%)
Updated
Sep 5, 04:59 PM (EDT)
Capitalization
272.4M
54 days until earnings call
Interact to see
Advertisement

IDYA vs VNDA

Header iconIDYA vs VNDA Comparison
Open Charts IDYA vs VNDABanner chart's image
IDEAYA Biosciences
Price$27.17
Change+$1.34 (+5.19%)
Volume$35.03K
Capitalization2.38B
Vanda Pharmaceuticals
Price$4.61
Change-$0.03 (-0.65%)
Volume$3.83K
Capitalization272.4M
IDYA vs VNDA Comparison Chart in %
Loading...
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VNDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
IDYA vs. VNDA commentary
Sep 06, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is IDYA is a Buy and VNDA is a Buy.

Interact to see
Advertisement
COMPARISON
Comparison
Sep 06, 2025
Stock price -- (IDYA: $25.83 vs. VNDA: $4.64)
Brand notoriety: IDYA and VNDA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: IDYA: 145% vs. VNDA: 116%
Market capitalization -- IDYA: $2.38B vs. VNDA: $272.4M
IDYA [@Biotechnology] is valued at $2.38B. VNDA’s [@Biotechnology] market capitalization is $272.4M. The market cap for tickers in the [@Biotechnology] industry ranges from $101.56B to $0. The average market capitalization across the [@Biotechnology] industry is $1.88B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

IDYA’s FA Score shows that 0 FA rating(s) are green whileVNDA’s FA Score has 1 green FA rating(s).

  • IDYA’s FA Score: 0 green, 5 red.
  • VNDA’s FA Score: 1 green, 4 red.
According to our system of comparison, both IDYA and VNDA are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

IDYA’s TA Score shows that 5 TA indicator(s) are bullish while VNDA’s TA Score has 7 bullish TA indicator(s).

  • IDYA’s TA Score: 5 bullish, 4 bearish.
  • VNDA’s TA Score: 7 bullish, 3 bearish.
According to our system of comparison, VNDA is a better buy in the short-term than IDYA.

Price Growth

IDYA (@Biotechnology) experienced а +3.61% price change this week, while VNDA (@Biotechnology) price change was -1.28% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +2.44%. For the same industry, the average monthly price growth was +9.90%, and the average quarterly price growth was +31.78%.

Reported Earning Dates

IDYA is expected to report earnings on Nov 11, 2025.

VNDA is expected to report earnings on Oct 29, 2025.

Industries' Descriptions

@Biotechnology (+2.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IDYA($2.38B) has a higher market cap than VNDA($272M). IDYA YTD gains are higher at: 0.506 vs. VNDA (-3.132). VNDA has higher annual earnings (EBITDA): -92.87M vs. IDYA (-380.2M). IDYA has more cash in the bank: 670M vs. VNDA (326M). VNDA has less debt than IDYA: VNDA (11.6M) vs IDYA (26.6M). VNDA has higher revenues than IDYA: VNDA (203M) vs IDYA (7M).
IDYAVNDAIDYA / VNDA
Capitalization2.38B272M875%
EBITDA-380.2M-92.87M409%
Gain YTD0.506-3.132-16%
P/E RatioN/A126.00-
Revenue7M203M3%
Total Cash670M326M206%
Total Debt26.6M11.6M229%
FUNDAMENTALS RATINGS
IDYA vs VNDA: Fundamental Ratings
IDYA
VNDA
OUTLOOK RATING
1..100
1510
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
82
Overvalued
PROFIT vs RISK RATING
1..100
70100
SMR RATING
1..100
9694
PRICE GROWTH RATING
1..100
4852
P/E GROWTH RATING
1..100
1003
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IDYA's Valuation (62) in the null industry is in the same range as VNDA (82) in the Biotechnology industry. This means that IDYA’s stock grew similarly to VNDA’s over the last 12 months.

IDYA's Profit vs Risk Rating (70) in the null industry is in the same range as VNDA (100) in the Biotechnology industry. This means that IDYA’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's SMR Rating (94) in the Biotechnology industry is in the same range as IDYA (96) in the null industry. This means that VNDA’s stock grew similarly to IDYA’s over the last 12 months.

IDYA's Price Growth Rating (48) in the null industry is in the same range as VNDA (52) in the Biotechnology industry. This means that IDYA’s stock grew similarly to VNDA’s over the last 12 months.

VNDA's P/E Growth Rating (3) in the Biotechnology industry is significantly better than the same rating for IDYA (100) in the null industry. This means that VNDA’s stock grew significantly faster than IDYA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
IDYAVNDA
RSI
ODDS (%)
Bearish Trend 4 days ago
77%
Bullish Trend 2 days ago
81%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
72%
Momentum
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
70%
MACD
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
69%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
73%
Advances
ODDS (%)
Bullish Trend 2 days ago
77%
Bullish Trend 8 days ago
70%
Declines
ODDS (%)
Bearish Trend 8 days ago
77%
N/A
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Interact to see
Advertisement
IDYA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VNDA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
OTCGX22.98N/A
N/A
MFS Mid Cap Growth R1
ARYWX13.41N/A
N/A
American Century Global Real Estate R
GERUX10.30N/A
N/A
Goldman Sachs Em Mkts Eq Insghts R6
HDSVX18.76N/A
N/A
Hodges Small Intrinsic Value Retail
HRVIX36.31N/A
N/A
Heartland Value Plus Investor

IDYA and

Correlation & Price change

A.I.dvisor indicates that over the last year, IDYA has been loosely correlated with SYRE. These tickers have moved in lockstep 61% of the time. This A.I.-generated data suggests there is some statistical probability that if IDYA jumps, then SYRE could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IDYA
1D Price
Change %
IDYA100%
+0.27%
SYRE - IDYA
61%
Loosely correlated
+1.07%
NRIX - IDYA
61%
Loosely correlated
-3.59%
CGON - IDYA
60%
Loosely correlated
+7.92%
IMNM - IDYA
60%
Loosely correlated
-4.39%
XENE - IDYA
58%
Loosely correlated
-0.49%
More

VNDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, VNDA has been loosely correlated with IVF. These tickers have moved in lockstep 40% of the time. This A.I.-generated data suggests there is some statistical probability that if VNDA jumps, then IVF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VNDA
1D Price
Change %
VNDA100%
-1.69%
IVF - VNDA
40%
Loosely correlated
-9.30%
OCUL - VNDA
40%
Loosely correlated
-1.85%
IDYA - VNDA
38%
Loosely correlated
+0.27%
ZYME - VNDA
38%
Loosely correlated
-0.42%
CGEM - VNDA
37%
Loosely correlated
-10.49%
More